performed the first large-scale analysis of serum PSA as a prostate cancer biomarker in 1987, convincingly demonstrating that PSA was more sensitive than prostate specific acid phosphatase (PSAP)/prostatic acid phosphatase (PAP) for monitoring the disease (1). The gene discussed is ACP3; the disease is prostate carcinoma.